Registry study for stage III liver cancer that cannot be removed
Part of Cancer clinical trials.
This registry study collects real-world information about people with stage III liver cancer that can’t be removed with surgery. It helps researchers better understand care and outcomes for different patients, including those with hepatitis B or C.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have liver cancer (hepatocellular carcinoma) that doctors say is unresectable, and it is stage III.
- Your liver function is in the Child-Pugh A or B range (about 7 points).
- You have not had any “systemic” (whole-body) cancer treatment yet.
- You can be evaluated at least one measurable tumor lesion and complete questionnaires with normal communication.
- If you have hepatitis B or C, your infection must be stable and managed in a specific way before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial studies how well a combination of chemotherapy, immunotherapy, and an anti-angiogenesis medicine works for advanced hepatocellular carcinoma (HCC), a type of liver cancer. It may help slow tumor growth and improve outcomes by attacking cancer in different ways.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This study looks at combining different treatments (local therapies, targeted therapy, and immunotherapy) for people with liver cancer that cannot be removed by surgery. The goal is to see how safe and effective these combinations are for a broad group of patients.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.